The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin
- PMID: 17102939
- DOI: 10.1007/s00210-006-0112-z
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin
Abstract
Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, so called statins, improve endothelial function and exert antiproliferative effects on vascular smooth muscle cells of systemic vessels. This study aimed at comparing the protective effects of two statins, pravastatin and atorvastatin, against monocrotaline (MC)-induced pulmonary hypertension in rats. Pravastatin or atorvastatin (PS or AS, 10 mg/kg per day) or vehicle were given orally for 28 days to Wistar male rats injected or not with MC (60 mg/kg intraperitoneally). At 4 weeks, MC-injected rats developed severe pulmonary hypertension, with an increase in right ventricular pressure (RVP) and right ventricle/left ventricle + septum weight ratio associated with a decrease in acetylcholine- or sodium-nitroprusside-induced pulmonary artery dilation observed in vitro. Hypertensive pulmonary arteries exhibited an increase in medial thickness and endothelial cell apoptosis and a decrease of endothelial nitric oxide synthase (eNOS) expression. MC-rat lungs showed a significant decrease of eNOS (P < 0.01) and increase of cleaved caspase-3 (P < 0.05) expression determined by Western blotting. PS (P = 0.02) but not AS (P = 0.30) significantly limited the development of pulmonary hypertension (RVP in mmHg: 30 +/- 3, 36 +/- 4 vs. 45 +/- 4 and 14 +/- 1 for MC + PS, MC + AS, MC, and control groups, respectively). Both statins significantly reduced MC-induced right ventricle hypertrophy [RV/left ventricular (LV) + S, in mg/g: 0.46 +/- 0.04, 0.39 +/- 0.03, 0.62 +/- 0.05 and 0.29 +/- 0.01 for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05),and reduced MC-induced thickening (61 +/- 6 microm, 82 +/- 5 microm, 154 +/- 4 microm, and 59 +/- 2 microm for MC + PS, MC + AS, MC, and control groups, respectively; P = 0.01) of small intrapulmonary artery medial wall, with MC + AS still being different from the control group. PS but not AS partially restored acetylcholine-induced pulmonary artery vasodilation in MC rats (E(max)=65 +/- 5%, 49 +/- 6%, 46 +/- 3%, and 76 +/- 4% for MC + PS, MC + AS, MC, and control groups, respectively; P < 0.05 for MC + PS vs. other groups). Both statins prevented apoptosis and restored eNOS expression of pulmonary artery endothelial cells as well as in the whole lung with a more pronounced effect with PS compared with AS. In conclusion, despite its effects on eNOS expression, apoptosis, and medial wall thickening, AS was unable to significantly reduce pulmonary hypertension and to restore endothelium-dependent relaxation, suggesting intermolecular differences between the two HMG-CoA reductase inhibitors in the protection against MC-induced hypertension.
Similar articles
-
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):401-14. doi: 10.1007/s00210-006-0082-1. Epub 2006 Aug 1. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16896805
-
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.Naunyn Schmiedebergs Arch Pharmacol. 2008 Sep;378(3):241-51. doi: 10.1007/s00210-008-0298-3. Epub 2008 Jun 10. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18542928
-
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.J Pharm Pharm Sci. 2009 Feb 4;11(2):118s-130s. doi: 10.18433/j34k5z. J Pharm Pharm Sci. 2009. PMID: 19203474
-
[Atherosclerosis in light of the evidence from large statin trials].Ann Ital Med Int. 2000 Jan-Mar;15(1):103-7. Ann Ital Med Int. 2000. PMID: 10842899 Review. Italian.
-
Statins: beneficial or adverse for glucose metabolism.J Atheroscler Thromb. 2006 Jun;13(3):123-9. doi: 10.5551/jat.13.123. J Atheroscler Thromb. 2006. PMID: 16835466 Review.
Cited by
-
Role of oxidative stress versus lipids in monocrotaline-induced pulmonary hypertension and right heart failure.Physiol Rep. 2021 Nov;9(22):e15090. doi: 10.14814/phy2.15090. Physiol Rep. 2021. PMID: 34816616 Free PMC article.
-
Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.Br J Pharmacol. 2008 Oct;155(4):444-54. doi: 10.1038/bjp.2008.239. Epub 2008 Jun 9. Br J Pharmacol. 2008. PMID: 18536743 Free PMC article. Review.
-
Efficacy and safety of statin therapy in pulmonary hypertension: a systematic review and meta-analysis.Ann Transl Med. 2019 Dec;7(23):786. doi: 10.21037/atm.2019.11.19. Ann Transl Med. 2019. PMID: 32042802 Free PMC article.
-
Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.Inflammation. 2014 Oct;37(5):1355-65. doi: 10.1007/s10753-014-9860-y. Inflammation. 2014. PMID: 24609836
-
Prognostic value of atherogenic index of plasma in pulmonary hypertension.Front Med (Lausanne). 2025 Jan 13;11:1490695. doi: 10.3389/fmed.2024.1490695. eCollection 2024. Front Med (Lausanne). 2025. PMID: 39871832 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
